Stay updated on Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial
Sign up to get notified when there's something new on the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page.

Latest updates to the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe record for a completed Phase 2 Sjögren’s syndrome trial is displayed, with details on study design, participant eligibility, interventions, outcomes, locations, and publications. Study history and supporting documents, including the protocol and statistical analysis plan, are also shown.SummaryDifference81%

- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA sitewide notice announces NIH website changes and says “Super Intelligence” will be used in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check29 days agoChange DetectedThe footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page previously displaying a study record now shows a 403 Forbidden error, with site chrome (navigation/footer) still visible, indicating the content is temporarily inaccessible.SummaryDifference19%

Stay in the know with updates to Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page.